2025
-
Increased Risk of Skin Cancer in Solid Organ Transplant Recipients Living with HIV.
Hanson M, Zakaria A, Leslie KS. J Am Acad Dermatol. 2025 Jan;92(1):181-183.
2024
-
De-escalation of corticosteroids and clonal remission in UBA1mutation-driven VEXAS syndrome with 5-azacytidine.
Trikha R, Kong KL, Galloway J, et al. Haematologica. 2024;109(10):3431-3434.
-
Immunotherapy for Advanced Skin Cancer in Kidney Transplant Recipients-The High-Risk Balancing Act.
Stump M, Arron S, Proby C. JAMA Dermatol. 2024 Aug 1;160(8):799-800.
-
Cumulative incidence and risk factors for cutaneous squamous-cell carcinoma metastases in organ transplant recipients: the SCOPE-ITSCC metastases study, a prospective multi-center study.
de Jong E, Genders R, Harwood CA, et al. J Am Acad Dermatol. 2024 Jun;90(6):1200-1209.
-
Topical JAK inhibition ameliorates EGFR inhibitor-induced rash in rodents and humans.
You Q, Chen L, Li S, et al. Sci Transl Med. 2024;16(752):eabq7074.
2023
-
How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
Kawsar A, Hussain K, Fearfield L. Br J Dermatol. 2023;189(Suppl 1):i3-i10.
-
VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist
Sterling D, Duncan ME, Philippidou M, Salisbury JR, Kulasekararaj AG, Basu TN. J Am Acad Dermatol. 2023;89(6):1209-1214.
-
Cutaneous squamous cell carcinoma tumor accrual rates in immunosuppressed patients with autoimmune and inflammatory conditions: A retrospective cohort study.
Granger EE, Groover M, Harwood C, et al. J Am Acad Dermatol. 2023.
-
Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management.
Ferrándiz-Pulido C, Leiter U, Harwood C, et al. Transplantation. 2023;107(7):1452-1462.
-
Skin cancer risk in people living with HIV: a call for action.
Reinhart JP, Leslie KS. Lancet HIV. 2024;11(1):e60-e62.
-
External Validation of the Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) in a Large European Solid Organ Transplant Recipient Cohort.
Gómez-Tomás Á, Bouwes Bavinck JN, Genders R, et al. JAMA Dermatol. 2023 Sep 1;159(9):1014.
2022
-
Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A, Edwards C, Patel P, et al. Br J Dermatol. 2022;187(6):981-987.
-
Interventions After First Post-Transplant Cutaneous Squamous Cell Carcinoma: A Proposed Decision Framework
Bottomley MJ, Massey PR, Thuraisingham R, et al. Transpl Int. 2022;35:10880.
-
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
Hasan ZU, Ahmed I, Matin RN, et al. . Br J Dermatol. 2022;187(3):324-337.
-
Clinicopathological features, MCPyV status and outcomes of Merkel cell carcinoma in solid-organ transplant recipients: a retrospective, multicentre cohort.
Ferrándiz-Pulido C, Gómez-Tomás A, Llombart B, et al. J Eur Acad Dermatol Venereol. 2022;36(11):1991-2001.
2021
-
The burden of cutaneous disease in solid organ transplant recipients of color
Kentley J, Allawh R, Rao S, et al. Am J Transplant. 2021;21(3):1215-1226.
-
Skin cancer multiplicity in lung transplant recipients: a prospective population-based study
Way M, Marquart L, Chambers DC, et al. Br J Dermatol. 2020;183(3):503-508.
-
Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases
Galván Casas C, Català A, Carretero Hernández G, et al. Br J Dermatol. 2020;183(1):71-77.
-
Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients: A Delphi Consensus Statement.
Massey PR, Schmults CD, Li SJ, et al. JAMA Dermatol. 2021;157(10):1219-1226. doi:10.1001/jamadermatol.2021.3180
-
Outcome of pretransplant melanoma after solid organ transplantation: an observational study.
Patras M, Decullier E, Lebbé C, et al. Transpl Int. 2021;34(11):2154-2165. doi:10.1111/tri.14109